back
Some
related articles :
Merck
Cuts Price for AIDs Drugs It Sells in China by About a Third (December 3,
2001) |
 |
China
Wants to Set Drug-Price Caps, Angering Pharmaceutical Companies
By
Leslie Chang and Karby Leggett
The Wall Street Journal, December 3, 2001
The State Development Planning Commission, which sets
drug prices, wants to impose a ceiling on the prices companies can charge
for both imported and domestically manufactured medicines. Under the plan,
a maker of a patented drug could sell it for no more than 30% to 40%
beyond what it would cost a generic Chinese manufacturer to produce.
Officials have said they want to cut prices across the board for generic
drugs as well, according to company executives who have been briefed on
the plans.
The regulation, which officials only now appear to be
putting into action after it was issued earlier this year, is being
condemned by foreign companies, which say such restrictive price caps are
untenable given the immense investments companies make to develop these
drugs. Companies likely to be affected include many of the world's
pharmaceutical giants, among them GlaxoSmith
Kline PLC, Merck
& Co., and Roche
Holding AG, all of which have invested in China in recent years.
"This is the biggest challenge our industry has ever
faced" in China, says the general manager of one foreign
pharmaceutical company. Implementation of price caps, he says, could lead
to widespread layoffs.
The affair is a reminder that China's imminent entry to
the World Trade Organization will not end the power of officialdom to
throw a company's entire business plan out of whack with a simple
directive. It also highlights the continuing lack of transparency in many
Chinese industries. In the opaque and highly regulated pharmaceutical
sector, many key details of how the government plans to calculate the
price caps are still unknown. "Which companies they are using to
calculate the cost, how far down they are going, we don't know," says
another industry executive.
What is certain is that China's health-care system needs
help, and cutting drug prices seems to appeal to Beijing as a quick-fix
solution. Many provincial and local governments that lack the funds to
support the nation's hospitals have cast them off on their own. As a
result, hospitals have come to rely on medicine sales for the bulk of
their revenue, unlike in other markets where there is more of a balance
between sales of drugs and other services. The situation leads to a
tendency to overprescribe medicines, which can carry public health risks.
The business of peddling medicines to hospitals, where an overwhelming 80%
to 90% of all medical sales in China take place, has also bred corruption,
with many hospitals accepting kickbacks that increase patient costs.
But imposing price caps won't solve the industry's
problems and could even exacerbate the tendency to overprescribe, critics
say. What needs to be done, they argue, is the far more difficult task of
putting hospitals on solid financial footing.
"If officials would fix the hospital-financing problem, they would
see that drug prices are not the problem," says the industry
executive.
FAIR USE NOTICE: This
page contains copyrighted material the use of which has not been
specifically authorized by the copyright owner. Global Action on Aging
distributes this material without profit to those who have expressed a
prior interest in receiving the included information for research and
educational purposes. We believe this constitutes a fair use of any such
copyrighted material as provided for in 17 U.S.C § 107. If you wish to
use copyrighted material from this site for purposes of your own that go
beyond fair use, you must obtain permission from the copyright owner.
|
